Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Simone Filosto(Kite (United States)), Jason R. Westin(The University of Texas MD Anderson Cancer Center), Craig A. Portell(University of Virginia), Soumya Poddar(University of California, Los Angeles), Carmen M. Warren(University of California, Los Angeles), Tan Trinh(Aadi (United States)), Xavier Poiré(Universität Hamburg), Justin A. Budka(Gilead Sciences (United Kingdom)), Paul Cheng(VA San Diego Healthcare System), Miguel Canales(Hospital Universitario La Paz), Zixing Wang(Aadi (United States)), Ethan G. Aguilar(Aadi (United States)), Adrian Bot(Unknown), Saran Vardhanabhuti, Lazaros J. Lekakis(University of Miami Hospital), Rhine R. Shen(Broad Institute), Sven de Vos(University of California, Los Angeles), Marco Schupp(Amgen (Switzerland)), Justin Chou, Christina To(Aadi (United States))
Cited by 49
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k